Internet Archive Scholar

Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis

Dr. Catherine R Hanna, Dr. Jose A Robles-Zurita, Andrew Briggs, Mrs. Andrea Harkin, Mrs. Caroline Kelly, Mr. John McQueen, Mrs. Karen Allan, Sarah Pearson, Henrik Hollander, Bengt Glimelius, Dr. Ramon Salazar, Eva Segelov (+4 others)
2021 Clinical colorectal cancer  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (986.0 kB)
https://web.archive.org/web/20220517143532/http://diposit.ub.edu/dspace/bitstream/2445/180102/1/PIIS1533002821000293.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Individual
more » ... y analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.
doi:10.1016/j.clcc.2021.04.001 pmid:33992542 fatcat:gpn26qb22va4zojdnxwq5qatle
Open Access
Citation

Dr. Catherine R Hanna, Dr. Jose A Robles-Zurita, Andrew Briggs, Mrs. Andrea Harkin, Mrs. Caroline Kelly, Mr. John McQueen, Mrs. Karen Allan, Sarah Pearson, Henrik Hollander, Bengt Glimelius, Dr. Ramon Salazar, Eva Segelov, Mark Saunders, Tim Iveson, Robert J Jones, Dr. Kathleen A Boyd. "Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis." Clinical colorectal cancer 20.3 (2021)